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Substantial progress has been made in characterising the risk associated with exposure to allergens in 28 
food. However, absence of agreement on what risk is tolerable has made it difficult to set quantitative 29 
limits to manage that risk and protect allergic consumers effectively. This paper reviews scientific 30 
progress in the area and the diverse status of allergen management approaches and lack of common 31 
standards across different jurisdictions, including within the EU. This lack of regulation largely explains 32 
why allergic consumers find Precautionary Allergen Labelling confusing and cannot rely on it. We 33 
reviewed approaches to setting quantitative limits for a broad range of food safety hazards to identify the 34 
reasoning leading to their adoption. This revealed  diversity of approaches from pragmatic to risk-based, 35 
but we could not find clear evidence of the process l ading to the decision on risk acceptability. We 36 
propose a framework built around the criteria suggested by Murphy and Gardoni (2008) for approaches to 37 
defining tolerable risks. Applying these criteria to food allergy, we concluded that sufficient knowledg  38 
exists to implement the framework, including sufficient expertise across the whole range of stakeholders 39 
to allow opinions to be heard and respected, and a consensus to be achieved. 40 
Key words: food allergy, tolerable risk, decision framework, risk management, risk assessment 41 
Highlights: 42 
• Quantitative limits for unintended allergen presence have in general not been defined across and 43 
within jurisdictions. 44 
• Inability to define what risk is tolerable is a major obstacle to defining those limits.  45 
• Diverse approaches (pragmatic to risk-based) have been adopted to define quantitative limits for 46 
other food safety hazards. 47 
• How tolerability decisions were reached in the case of those hazards is unclear. 48 
• We propose a framework for transparent decisions on risk tolerability, founded on full 49 
participation of stakeholders. 50 









1 Introduction 52 
Significant progress has been achieved in characterizing the risk to people with food allergies from 53 
exposure to food allergens, both at an individual and t a population level. At a population level, this as 54 
facilitated the proposed use of management threshold  t  guide the need for declaring the presence of 55 
unintended allergens, based on Reference Doses derive  f om food challenges in allergic patients. Many 56 
stakeholders across the food allergy community remain concerned that guidelines based on these 57 
Reference Doses may still not protect the occasional person with food allergy: either due to extreme 58 
sensitivity (i.e. reacting to very low doses of allergen), reactivity (responding with severe symptoms to 59 
exposure) or unusually high consumption levels (eating large portions of food with unintended allergen 60 
presence). As a result, acceptance of this approach h s been limited, hindering the application of risk-61 
based approaches to this aspect of food safety management. Failure to adopt risk-based approaches does 62 
not serve society well, particularly those directly affected by food allergy and their carers. In addition, the 63 
lack of uptake exposes other stakeholders to unnecessary costs and impacts such as food waste, as well as 64 
uncertainty regarding compliance with food safety measures. A critical element missing from current 65 
discussions is the absence of any transparent consideration of what level of risk is tolerable, in relation to 66 
the consequences of unintended allergen presence at an individual and public health level. 67 
 68 
The aim of this paper is to describe the current situation in the management of unintended allergen 69 
presence. In addition, we will discuss the obstacles to defining a tolerable risk and therefore an 70 
appropriate level of protection in food allergy, and suggest a way forward. 71 
2 The science behind the derivation of safe dose levels of allergens 72 
For many years, it was unclear whether thresholds – a level of allergen exposure below which no 73 
symptoms occur – existed in food allergy. It seemed that the smallest amounts of allergen exposure could 74 
elicit allergic reactions. However, from a biological perspective, thresholds should be expected to exist, 75 









estimate population threshold levels was first formally proposed in 2002 (Bindslev-Jensen et al., 2002). 77 
Although this idea was quite revolutionary at the time, it was clear that if population thresholds derived 78 
using this approach were to try and achieve zero risk in all allergic individuals, the levels would most 79 
likely be so low for most allergens that they would not be practical for most applications and result in an 80 
abundance of precautionary allergen labelling (PAL), a voluntary approach to inform allergic consumers 81 
of the unintended presence of a food allergen. 82 
 83 
This was followed by a paper by (Crevel et al., 2007) who discussed the concept of modelling such data84 
to determine the amounts of total allergenic protein – called eliciting dose (ED) – at which a certain 85 
percentage of the allergic population would be predict  to experience allergic symptoms (EDx at which 86 
x% is expected to respond). Since then, several papers have been published exploring this idea and 87 
reporting results of human challenge (provocation) studies and modelling the data generated (Allen et al., 88 
2014a; Taylor et al., 2014). This forms the basis for the derivation of Reference Doses from EDx values. 89 
While Reference Doses can be calculated for any given proportion of the allergic population, in practice 90 
the most common Reference Doses reported are for the amounts predicted to provoke objective reactions 91 
in 1% and/or 5% of the allergic population (termed ED01 and/or ED05 respectively). For an overview of 92 









Table 1: Definitions of selected terms used in the context of thresholds 95 
Term Definition 
Eliciting dose The dose (mg) predicted to provoke reactions in a defined proportion of the allergic population 
(ED01, ED05, ED10 etc.), derived from the dose distribution of individual minimum eliciting doses 
(MEDs). The suffix describes the proportion e.g. ED01 = the dose predicted to provoke reactions in 
1% of the at-risk allergic population 
Reference dose The dose (mg) derived from an acceptably low Eliciting dose (e.g. ED01, ED05) chosen as a health- 
based intake limit. 
Action level The concentration (mg/kg) in food as consumed, containing the Reference dose based on specified 
conditions of exposure (portion size etc).  
Threshold (individual, 
clinical) 
The lowest dose capable of eliciting an allergic reaction in an individual (also called the minimum 
eliciting dose - MED) 
Threshold (regulatory) The maximum concentration of an allergenic food deemed to pose a tolerable risk to the at risk 
population, given their susceptibility and the circumstances of exposure e.g. 20 mg gluten/kg is the 











A significant advance occurred in 2014 when the results from a joint effort by TNO in the Netherlands 97 
and FARRP in the US through the VITAL Scientific Expert Panel were published. This presented ED 98 
values for 11 major allergenic foods (Allen et al.,2014a; Taylor et al., 2014), which were adopted by the 99 
Australia-New Zealand Allergen Bureau as a basis for Reference Doses in their Voluntary Incidental 100 
Trace Allergen Labelling (VITAL) programme (www.allergenbureau.net/vital/). For foods with sufficient 101 
data, the ED01 was used. For other allergens with less data, the low r 95% confidence interval of ED05 102 
was used for the Reference Dose. Since then, many food companies and authorities have embraced the 103 
idea of using an ED modelling approach with Reference Doses for risk management purposes, including 104 
the application of PAL. However, consensus over a single harmonised approach has not yet emerged 105 
within any jurisdiction (see next section). Meanwhile, further research has generated additional data and 106 
methodologies to support and develop the use of Reference Doses. Several groups have performed studies 107 
to validate ED modelling through single-dose challenge studies. Hourihane et al. (2017) demonstrated 108 
that challenging unselected people with peanut allergy attending allergy clinics, at a dose expected to 109 
elicit an objective allergic reaction in 5% of the participants, did not result in more than 5% reactions; all 110 
reactions were of mild severity and did not require pharmacological intervention. Single dose challenges 111 
for other allergenic foods were performed in the framework of the EU project iFAAM, 112 
(http://research.bmh.manchester.ac.uk/iFAAM). These data are yet to be published, but support the safety 113 
of the Reference Doses used, although participant numbers were insufficient for the results to confirm 114 
those doses within the same confidence intervals as the peanut study by Hourihane et al. (2017). The 115 
TRACE study, funded by the UK Food Standards Agency, provided further confidence that the Reference 116 
Dose for peanut proposed by Taylor et al. (2014) remains appropriate, even in the presence of a number 117 
of co-factors (sleep deprivation, vigorous exercise) (Dua et al., 2019), indicating that there is no need for 118 
further uncertainty factors to be incorporated into the derivation of Reference Doses. 119 
 120 
TNO and FARRP continued to collect food challenge data and expanded their joint database from ~1800 121 










experts to develop a Model Averaging approach to allow the calculation of one single ED value based on 123 
various statistical models, rather than calculating different ED values based on the different models and124 
deriving Reference Doses through expert judgement (arXiv:1908.11334v1 [stat.AP] Wheeler et al., 2019). 125 
Model Averaging is the preferred approach for derivation of benchmark values, such as Reference Doses, 126 
when there is no biological reason to prefer one model ver another (EFSA Scientific Committee, 2017). 127 
Based on the expanded database and Model Averaging, TNO and FARRP have performed new ED value 128 
calculations for 14 different allergenic foods, theresults of which largely support the original VITAL 2.0 129 
values, notwithstanding minor changes due to the larger datasets available for most allergens (Remington 130 
et al., 2020). These new ED calculations were recently used to update the Reference Doses in the VITAL 131 
program (VITAL 3.0: http://allergenbureau.net/vital/vital-science/). Finally, TNO and FARRP are 132 
analysing data in the threshold database in more detail, to extract information on the nature of symptoms 133 
of allergic reactions elicited at dose levels in low ED-ranges, to further clarify the level of protection 134 
likely conferred by Reference Doses derived from them (Blom et al., in preparation). This will also be135 
supplemented by further analysis of the TRACE results, focussing on symptom severity. 136 
3 Diversity in management decisions from different countries  137 
Regulation in many countries mandates that allergens present as ingredients are labelled regardless of the 138 
level of inclusion, but the use of PAL for allergens potentially present in foods due to cross-contact is not 139 
explicitly regulated in most countries, and is primarily applied on a voluntary basis and without clear 140 
guidance. 141 
 142 
2To date, only four countries (Argentina, Japan, South Africa and Switzerland) have regulations relating 143 
to PAL (Allen et al., 2014b), all taking different approaches and with only two applying a risk-based 144 
approach using a labelling threshold. For example, th  use of ‘may contain’ statements is prohibited in 145 
Argentina, unless authorisation is sought (Lopez, 2018). The first country to define a labelling threshold 146 










above 1000ppm to be declared. PAL is permitted in Switzerland but only for allergens potentially present 148 
due to cross-contact and above the defined threshold. Japan has defined a threshold (10µg per g of food 149 
(10ppm)) above which all regulated allergens (whether deliberately added or not) must be declared, but 150 
Argentina have not. Whilst the presence of allergens below 10ppm does not require labelling in Japan, 151 
alternative PAL statements may be used. South Africa permits the use of PAL but only where there is a 152 
documented risk assessment demonstrating potential cross-contact despite Good Manufacturing Practices 153 
(GMP). Figure 1 illustrates graphically how the single regulatory thresholds set by Switzerland and Japan 154 
compare with the population ED distributions for vaious allergens for a portion size of 200g. 155 
 156 
 157 
Figure 1. Quantitative guidance for (precautionary) allergen labelling. The figure illustrates graphically how the 158 
single regulatory thresholds set by Switzerland (1000 ppm [mg/kg]) and Japan (10 ppm [mg/kg]) compare with the 159 
population ED-distributions for various allergens for a portion size of 200 g. ED-distributions based on the 2011 160 










In the EU, the European Commission (EC) is required to adopt an Implementing Act on PAL as part of 162 
the 2011 Food Information for Consumers (FIC) Regulation. To date, the EC have set up a working group 163 
to study PAL, organised a stakeholder workshop and published a report (June 2016). Whilst there was 164 
consensus at the workshop that PAL should be based on risk assessment combined with Reference Doses, 165 
there have been no further activities in this area. This has led to a diversity of management decisions 166 
being proposed by different EU countries, though none have been adopted into law. 167 
 168 
Several EU countries appear to be taking a ‘zero tolerance’ approach, such that the mere detection of 169 
unintentionally present allergen requires PAL, no matter the amount detected. Others appear to align with 170 
the consensus from the EC workshop in taking a risk-based approach. However, a single harmonised 171 
approach has yet to emerge and the recommended threshold levels vary. This lack of consensus also has 172 
implications not only for PAL application, but also for food recalls (Bucchini et al., 2016). The approach 173 
regarding risk communication to consumers also varies among Member States.  174 
 175 
Prior to the aforementioned workshop, in 2015, a collab rative project was undertaken by the Danish, 176 
Swedish, Finnish and Norwegian food control authoriies looking into ‘Undeclared allergens in food’. 177 
The report (Bolin and Lindeberg, 2016) includes a risk assessment using published ED data available at 178 
the time, indicating support for a risk-based approach to PAL using such data, though since then no 179 
further or updated guidance has been produced.  180 
 181 
In 2016, the Dutch Bureau for Risk Assessment and Research Programming (BuRO) of The Netherlands 182 
Food and Consumer Product Safety Authority (NVWA, 2016) concluded that a quantitative risk-based 183 
approach could be applied to allergens in food and proposed the use of provisional Reference Doses. 184 
They proposed Reference Doses that correspond to the l west ED01 values obtained by the Weibull model 185 
of the same studies on which Allergen Bureau VITAL® 2.0 Reference Doses are based. The VITAL® 2.0 186 










the final reference dose was established dependent on the fit of the mathematical models. The BuRo-188 
proposed temporary provisional reference doses are list d in Table 2 and were proposed in a 189 
recommendation to Dutch Ministries (NVWA, 2016), however there has been no formal follow-up to date 190 
by the Ministries regarding this recommendation. 191 
 192 
In 2017, the Scientific Committee of the Belgian Federal Agency for the Safety of the Food Chain 193 
(SciCom, 2017) also issued an opinion on Reference Doses, to provide information to assist with 194 
managing risks arising from the unintended presence of allergens in food, and proposed Reference Doses 195 
which they estimated would protect 95 to 99% of the all rgic population, also based on the same studies 196 
on which Allergen Bureau VITAL® 2.0 Reference Doses are based. In contrast to the Reference Doses 197 
proposed by BuRO, these Reference Doses are generally higher than the VITAL® 2.0 equivalent: the 198 
Committee proposed to use the lower limit of the 95% confidence interval of the ED05, giving preference 199 
to the lowest value obtained by means of a log-logistic or a log-normal model on the largest dataset 200 











Table 2. Reference Doses proposed by both the Dutch Bureau for Risk Assessment and Research Programming (BuRO) and Belgian Federal Agency for the 203 
Safety of the Food Chain (FASFC) alongside the VITAL® 2.0 and 3.0 reference doses (RD). 204 
Allergen 
VITAL® 2.0 RD*  
(mg protein per portion) 
Netherlands Proposed RD 
(mg protein per portion) 
Belgium Proposed RD 
(mg protein per portion) 
VITAL® 3.0 RD 
(mg protein per portion) 
Peanut 0.20 0.015 1.1 0.20 
Milk 0.10 0.016 1.2 0.20 
Egg 0.03 0.0043 0.3 0.20 
Hazelnut 0.10 0.011 0.5 0.10 
Soy 1.00 0.078 2.9 0.50 
Wheat 1.00 0.14 1.3 0.70 
Mustard 0.05 0.022 0.1 0.05 
Lupin 4.00 0.83 4.5 2.6 
Sesame 0.20 0.1 0.4 0.10 
Shrimp 10.00 3.7 12.1 25 
Celery N/A N/A N/A 0.05 
Fish N/A N/A N/A 1.30 
Cashew N/A N/A N/A 0.05 
Walnut N/A N/A N/A 0.03 
*the Official Food Control Laboratories in Germany adopted VITAL® 2.0 RDs 205 












In 2014 the Official Food Control Laboratories in Germany established internal action levels, based 209 
on VITAL 2.0 Reference Doses, for assessing samples (Bundesamt für Verbraucherschutz und 210 
Lebensmittelsicherheit (BVL), 2015; Waiblinger and Schulze, 2018). This approach converts the 211 
VITAL 2.0 Reference Doses from mg protein per portion of food, to mg foodstuff per portion and 212 
then to a reference concentration assuming a 100g portion of food; and then, finally, to an ‘Action 213 
Value’ based on current analytical capability. These Action Values are not to be considered legal 214 
threshold values, but internal values used by official control laboratories to drive recommendations o 215 
the need for further investigations when allergens are found in products without them being declared. 216 
They are expected to be updated regularly as new analytical and human data become available. 217 
 218 
In 2019, VITAL® 3.0 Reference Doses were published (Allergen Bureau, 2019) as described in 219 
Section 2, using a ‘stacked’ model averaging approach ( rXiv:1908.11334v1 [stat.AP] Wheeler et al., 220 
2019) applied to the extended TNO-FARRP set of challenge data. Whereas the VITAL® 2.0 221 
Reference Doses were based on the ED01 or 95% lower confidence interval of ED05 depending on 222 
quantity and quality of available data, the VITAL® 3.0 Reference Doses, are based solely on the ED01 223 
and are also listed in Table 2. 224 
 225 
Most recently, in the Czech Republic, national recommendations for voluntary labelling of 226 
unintentional presence of allergens have been prepared ‘on the basis of a consensus of representatives 227 
of the Ministry of Agriculture, the State Agriculture and Food Inspection Authority and the State 228 
Veterinary Administration’ (www.eagri.cz, 2018). These recommendations appear to take a different 229 
approach to those previously mentioned, recommending (i) amounts of allergen in a food intended for 230 
final consumers, which can be regarded as “zero” and therefore not requiring PAL; and (ii) maximum 231 
amounts that can be considered as "trace amounts", stating that above this it is no longer considered as 232 
unintended contamination, thus misleading the consumer. These amounts are given as concentrations 233 
(not RDs), for some allergens the protein content is indicated and for others not, and the ‘maximum 234 
values considered "zero"’ are based on the ‘limit of detection’ of commonly used analytical methods, 235 










allergens occur at lower concentrations than allergens added as ingredients, an assumption which is 237 
not supported by experimental evidence (see Blom et al 2018, for example).  238 
 239 
Globalisation of the food chain and movement of peopl  is such that the current diversity of 240 
approaches to PAL adds complexity to food production and causes further confusion amongst allergic 241 
consumers. A harmonised global risk-based approach would be optimal and as such, steps being taken 242 
by the Codex Alimentarius Commission to develop a Code of Practice for Allergen Management for 243 
Food Business Operators (www.fao.org/fao-who-codexalimentarius, 2018) as well as ultimately 244 
guidance on the application of PAL (www.fao.org/fao-who-codexalimentarius/, 2019) at an 245 
international level constitute an important move in this direction. 246 
4 The risk as it looks now with Precautionary Allergen Labelling (PAL) 247 
The use of PAL has increased over the past decades, triggered by the mandatory labelling of common 248 
allergenic ingredients and an uncertain regulatory and risk assessment landscape. There has been a 249 
further increase in the use of PAL by catering establishments on non-prepacked foods, following the 250 
implementation of the 2011 Food Information for Consumers (FIC) Regulation in the EU. In most 251 
countries, PAL is voluntary, and there is huge variation in the way decisions regarding the use of 252 
precautionary statements are made, as well as a lack of transparency and harmonized practice (see 253 
section 3). 254 
 255 
The indiscriminate use of PAL has important impacts on patients with food allergy, their families and 256 
healthcare providers. They significantly reduce food choices, increasing the cost of food and lead to 257 
devaluation of the warning: patients, in particular adolescents, are increasingly ignoring the warnings 258 
and using proxy markers of unintended allergen presence, such as brand, retailer, etc (Barnett et al., 259 
2011; Barnett et al., 2013; Ben-Shoshan et al., 2012; Cochrane et al., 2013). This is partly due to 260 
mistrust, partly because PAL appears on so many products that they feel their food choice is impaired. 261 
In addition, food-allergic individuals ignore PAL on food products which they have previously eaten 262 










absence of PAL (Allen and Taylor, 2018; Pele et al., 2007). Products with PAL often do not contain 264 
the stated allergen(s), and products without PAL may still contain clinically significant amounts of 265 
unintended allergen(s). A recent study (Blom et al., 2018) found that precautionary warnings for 266 
specific allergens did not correlate with either the presence, absence or concentration of 267 
unintentionally present allergens detected analytically. While the mandatory declaration of major 268 
allergens as ingredients aims to enable consumers with food allergies to make safe food choices, the 269 
unregulated use of PAL works against this. In light of he new results from the Dutch study, which 270 
support findings from an earlier UK study (FSA project FS241038, 2014; FSA project FS305014, 271 
2014; Remington et al., 2015) that declaration of an allergen in the PAL statement does not 272 
necessarily imply that there is not another unstated unintended allergen present, allergic consumers 273 
are unable to do a risk assessment for unintended all rgen presence by just referring to the label 274 
(Figure 2). 275 
 276 
The many uncertainties around labelling can increase the risk of accidental reactions in patients 277 
(Versluis et al., 2015). In a recent prospective study, the number of unexpected reactions was around 278 
1 per person per year (Michelsen-Huisman et al., 2018). Strikingly the majority of these events were 279 
at least moderately severe and at least 28% included anaphylaxis; despite most patients not seeking 280 
medical attention, there were still 6 emergency hospital visits among the 108 patients. Further 281 
analyses by Blom et al. (2018) found that in products ausing an accidental reaction, levels of 282 
undeclared allergenic constituents (cow’s milk, hen’s egg, peanut, hazelnut, walnut) varied from 4 283 
ppm to 5000 ppm (protein). When actual amounts consumed were calculated by including the food 284 
intake of the patient, the estimated level of allergen exposure varied from 0.4-170mg (protein) for 285 
peanut, 0.01-3.5mg for hazelnut, 0.1-42mg for sesam, 0.09-9mg for egg, and 0.13-123mg for milk. 286 
For all cases where culprit allergens were detected, the intake of at least one unintended allergen 287 
exceeded the Reference Dose or a culprit allergen with a yet unknown Reference Dose was present 288 
(on the basis of Taylor et al. (2014)). This implies that the Reference Doses as proposed by Taylor et 289 
al, 2014, might be highly protective in practice. The study also showed that a large variety of products 290 










number of foods such as bread (rolls), cookies, chocolates, meat and meat products. Important to note,292 
while eating out of home is often thought to be the main risk factor for unexpected allergic reactions, 293 
prepacked foods were the main cause of unexpected reactions in this prospective study in the 294 
Netherlands. 295 
296 
Figure 2. Scenarios for the presence or absence of precautionry allergen labelling (PAL). Modified, from 297 
DunnGalvin et al. (2015). 298 
 299 
Together these data indicate that PAL currently 300 
1. is not related to the actual risk  301 
2. does not always cover the right allergens 302 
3. limits food choices unnecessarily  303 










5. is increasingly ignored 305 
6. is of limited value for patients due to the inconsistencies in its application 306 
5 How have similar problems been handled in other areas? 307 
It is clear that PAL is a tool which is often used injudiciously, and its power as part of risk 308 
management has therefore been seriously eroded. It can be argued that one of the reasons for this is 309 
the apparent lack of agreement on an appropriate lev l of protection for the various regulated 310 
allergens in potential scenarios of unintended presence. This translates to a question of which level of 311 
residual risk society is prepared to accept, considering that for several food safety risks, an absolute 312 
zero risk probably does not exist nor is achievable. It is therefore interesting to explore how other 313 
food safety risks are being managed. Table 3 summarises the criteria that have been used in deciding 314 
limits to protect public health in the case of other food safety risks, as detailed below.  315 
 316 
5.1. Acrylamide 317 
In 2002 food industry and authorities were surprised by the presence in many heated foods of 318 
acrylamide at levels significantly greater than those predicted to cause more than the generally 319 
accepted one additional case of cancer per million people exposed. Industry started an approach to 320 
lower the acrylamide levels in food, not aimed necessarily at achieving safe levels but to result in 321 
lower levels compared to those detected at the time. The Codex Alimentarius Commission 322 
recommended that industry takes mitigation measures (FAO/WHO Codex Alimentarius, 2009). 323 
FoodDrinkEurope developed an Acrylamide Toolbox, based on the ALARA (As Low As Reasonably 324 
Achievable) principle (FoodDrinkEurope, 2019). Off the back of this, other industry organisations 325 
supported the management of acrylamide levels in food by issuing foodstuff specific guidance, e.g. a 326 
pantone chart was developed by Good Fries EU (2019). In 2018 (effective date) benchmark dose 327 
levels were implemented in the EU (European Commission, 2017b), not with the aim of achieving 328 












Table 3. Criteria used in setting regulatory thresholds.  332 
 333 





























20 ppm n.r. + 
Clinical disease 
and histological 
changes in the gut 
The majority of persons 
with coeliac disease 










 EU: Fish and Fish products with 
high histidine content: Mean value 
is < 100 ppm and no value > 200 
ppm. Higher values for fermented 
fish products. 
US: Decomposition action level is 








No EU or US limits for 
histamine in other 
products high in 
histamine e.g. cheese. 








10 ppm n.r. + 
Acute symptoms 
such as asthma 
and urticaria 
LOAEL not known, but 
probably the majority of 
sulphite sensitive 
+ 










No regulatory limits. 
Appropriate mitigation measures 
should be laid down to reduce 
levels 






MOE for low concern 
level in relation to cancer 
is > 10,000 (ALARA) 









20/50 samples may exceed 1000 
cfu/g for broiler meat carcasses 
+  




The suggested threshold 
is expected to result in a 
calculated risk reduction 
of > 50% compared to 
previous levels 
 
The threshold will be 
reduced gradually down 
to 10/50 samples that 
may exceed 1000 cfu/g 
by 2025 
8 
n.r.: not relevant; LOAEL : Lowest Observed Adverse Effect Level; MOE : Margin Of Exposure; ALARA : As Low As Reasonably Achievable; cfu: colony 334 
forming units; GI : Gastro-intestinal. 335 
1: (Joint FAO/WHO Food Standards Programme CODEX ALIMENTARIUS Commission, 2008) 336 
2: (European Commission, 2005) 337 
3: (FDA, 2005) 338 
4: (EFSA, 2014) 339 
5: (Federal Register, 1986) 340 
6: (European Commission, 2017b) 341 
7: (EFSA Panel on Contaminants in the Food Chain (CONTAM), 2015) 342 











Acrylamide is a genotoxic carcinogen, so it is not c nsidered to have a threshold below which no risk 345 
exists i.e. it is not possible to establish a safe lev l of exposure. The European Food Safety Authority 346 
(EFSA) therefore uses a ‘margin of exposure’ (MOE) approach. For substances that are both 347 
genotoxic and carcinogenic, a MOE of 10,000 or higher (based on the BMDL101 (EFSA, 2009; EFSA 348 
Scientific Committee, 2017) derived from benchmark dose modelling of animal studies as the Point of 349 
Departure and taking into account overall uncertainties in the interpretation) would be of low concern 350 
from a public health perspective. The MOE values for acrylamide range from 50 to 425: since these 351 
are all substantially lower than the value of 10,00 the Commission’s Standing Committee on Plants, 352 
Animals, Food and Feed concluded that  although the available human studies have not demonstrated 353 
acrylamide to be a human carcinogen, the MOEs across surveys and age groups indicate a concern 354 
with respect to neoplastic effects at current levels of exposure (EFSA Panel on Contaminants in the 355 
Food Chain (CONTAM), 2015; European Commission, 2017b). Thus, there is a principle that (i) 356 
zero risk is not possible, and (ii), the most effective strategy is one of risk minimisation rather 357 
than risk elimination . 358 
 359 
5.2. Histamine  360 
EFSA assessed the incidents of histamine intoxication during 2010-2015 in some EU countries and 361 
found 191 outbreaks linked to 1060 cases, resulting in 107 hospitalizations but no deaths (EFSA, 362 
2017). Fish and fish products were reported as the major cause, but also shellfish/crustacea and dairy 363 
products (and specifically cheese) were involved (EFSA, 2017). These findings are consistent with the 364 
EFSA Opinion on risk-based control of biogenic amine formation in fermented foods, that established 365 
dried anchovies, fish sauce, fermented vegetables, cheese, other fish/fish products and fermented 366 
sausages as the major causes of concern (EFSA Panelon Biological Hazards (BIOHAZ), 2011b). 367 
While doses of 50mg histamine for healthy individuals were reported to cause no adverse health 368 
effects, this did not apply to people with histamine tolerance, for whom only a below-detectability 369 
level was considered protective (EFSA Panel on Biological Hazards (BIOHAZ), 2011b). 370 











The Dutch Food Safety Authorities assessment of the risk of biogenic amines in cheese refers to 36mg 371 
histamine as the smallest amount that can lead to symptoms in healthy people (Recommendations on 372 
risks of biogenic amines in cheese, 2010). Like EFSA, they state that a lower value is appropriate for 373 
~1% of the population who suffer from histamine intolerance. Considering a portion size of 50g, they 374 
derived a preliminary risk-based limit for the healthy population of 720mg histamine/kg cheese. Of 375 
note, since this limit is based on human observations, no safety margins/uncertainty factors were 376 
applied. 377 
 378 
The USA Food and Drug Administration (FDA) Policy Guide (FDA, 2005) considers 500ppm 379 
histamine in fish such as tuna as a health hazard, but FDA can act based on the decomposition action 380 
level of 50ppm rather than on the hazard action level. While the 500ppm hazard action level has been 381 
established in the US for tuna, it was highlighted that similar data need to be gathered for other fish 382 
species and other foods. Fermented fish and cheese products were highlighted to be of importance in 383 
that respect (Taylor, 1985). 384 
 385 
The available information on histamine clearly demonstrates areas of residual risk that have not been 386 
regulated so far: 387 
- While products such as fermented vegetables, shellfish/crustacea, fermented sausages and 388 
dairy products (specifically cheese) can contain histamine, only fish products have been 389 
regulated in the EU (European Commission, 2005). 390 
- The Dutch food safety authorities have set a provisi nal limit of 720mg histamine/kg cheese. 391 
This limit is provisional, until EFSA sets a limit. 392 
- In the legislation, the higher sensitivity of consumers with histamine-intolerance has not been 393 
considered. 394 
Although actual risk management rationales are not always traceable, risk management levels have 395 
been set for histamine in the presence of residual risks. At some stage, the residual risk inherent in the 396 










concept that for some individuals (in this case, those with histamine-intolerance), the proposed risk 398 
management levels may not confer complete protection.  399 
 400 
5.3. Sulphites 401 
Sulphites are an interesting case study to consider in the context of tolerable risk and food ingredients, 402 
because they cause similar symptoms to food allergy in a subset of sensitive individuals (Corder and 403 
Buckley, 1995; Vally and Misso, 2012). The mechanisms remain unclear by which sulphites can 404 
cause symptoms such as bronchoconstriction, and whilst people with asthma are the primary 405 
population that appears to be particularly at risk, there are some reports of reactions in non-asthmatics 406 
too. 407 
 408 
The US FDA acted in 1986 to implement labelling of foods containing levels of sulphites ≥10 ppm 409 
(10 mg/kg). The aim was to quickly reduce the risk from ‘hidden’ sulphites to sulphite-sensitive 410 
individuals, despite a lack of data to support this action level: the FDA stated “that the available 411 
information is inconclusive regarding whether there is a biological threshold level for sulfiting agents 412 
below which sensitive individuals will not experience adverse reactions”. Accordingly, the FDA did 413 
not use a biological criterion for determining what constitutes a significant level of sulphites, but 414 
rather based its level on analytical capability, and considered “that the regulatory threshold of 10ppm 415 
sulphite will adequately protect consumers of large servings as well as those who consume several 416 
servings of different foods containing sulfiting agents”. 417 
 418 
This level found its way into Codex and EU regulation. In 2014 EFSA published a systematic review 419 
concluding that ‘Minimal eliciting doses have not been systematically assessed and the smallest 420 
concentration of sulphites able to trigger a reaction in a sensitive person is unknown’ (EFSA, 2014). 421 
Despite this, many countries (EFSA, 2014; Federal Register, 1986) have regulations requiring sulphites 422 
to be declared at concentrations of 10ppm (10mg/kg) or higher in foods. Whilst this limit is stated to be 423 
based on the LOD of analytical methods at the time (1980), the level of protection provided across 424 










data that was available (Federal Register, 1986). Thus, there is precedent for the application of a 426 
Reference Dose based on available (but not necessarily completely comprehensive) data in the 427 
protection of the public from what is considered in legislation to be an allergen. 428 
 429 
5.4 Microbiology  430 
Another example of how a prevalent food safety riskis being managed is the manner in which EU 431 
authorities have regulated the presence of Campylobacter in broiler meat carcasses. A joint European 432 
Centre for Disease Prevention and Control (ECDC)/EFSA review in 2017 reported the occurrence of 433 
246,158 cases of campylobacteriosis (EFSA and ECDC, 2018). In terms of root cause analysis, EFSA 434 
reported in 2008 an average contamination rate of broiler carcasses with Campylobacter of 75.8% , 435 
with significant variations between member states and slaughterhouses (EFSA, 2010). Moreover, 436 
EFSA established that “the handling, preparation and consumption of broiler meat accounted for 20-437 
30% of human cases of campylobacteriosis, while 50-80% could be attributed to the chicken reservoir 438 
as a whole” (EFSA Panel on Biological Hazards (BIOHAZ), 2010). In an additional Opinion in 2011, 439 
EFSA concluded that “a public health risk reduction of >50% or >90% could be achieved if all 440 
batches complied with microbiological criteria with a critical limit of 1000 or 500 Colony Forming 441 
Units per gram (CFU/g) of neck and breast skin respectively, while 15% and 45% of all tested 442 
batches failed to comply with these criteria” (EFSA Panel on Biological Hazards (BIOHAZ), 2011a). 443 
 444 
ADAS UK Ltd carried out a report for DG SANCO of the European Commission (Elliott et al., 2012) 445 
on the cost/benefit analysis of setting certain control measures for reduction of Campylobacter in 446 
broiler meat at different stages of the food chain. It’s main conclusion was that “setting a process 447 
hygiene criterion for Campylobacter in broiler carcasses would best balance reducing human 448 
campylobacteriosis attributed to the consumption of poultry meat, and adverse economic 449 
consequences from the application of the criterion.” (recital 8, EU Reg 2017/1495). 450 
 451 
Finally, with the publication of EU Commission Regulation 2017/1495 (European Commission, 452 










with a maximum of 20/50 samples allowed to exceed this value. Over time, this ratio will gradually 454 
reduce to 10/50 samples by 2025.  455 
 456 
The campylobacter case study can therefore be considered as an example where, after thorough risk 457 
assessment and considering additional factors such as t e economic consequences of the proposed 458 
measures, a practical risk management approach is taken to benefit the health of EU consumers, 459 
whilst not insisting on zero risk. 460 
 461 
5.5. Coeliac disease and definition of the standard for gluten-free foods 462 
5.5.1. Coeliac disease 463 
Coeliac disease is an immune-mediated disease triggered by ingestion of gluten, which is found in 464 
cereals such as wheat, barley and rye. There is international agreement on a threshold for gluten in 465 
gluten-free foods of 20ppm. This was based on observations that the Lowest Observed Adverse Effect 466 
Level (LOAEL) for gluten in consumers with coeliac disease was about 50mg/day and, taking dietary 467 
consumption patterns into account, this would ensure that gluten exposure would remain well below 468 
this amount (Codex Alimentarius Commission, 2005). 469 
. An important factor in selecting this level was the ability to verify it analytically. The US-FDA also 470 
adopted 20ppm as the gluten threshold, but conducte a health risk assessment to establish an amount 471 
below which no adverse effects could be observed. This derived a No Observed Adverse Effect Level 472 
(NOAEL) of 0.015mg gluten per day. However, in formulating their conclusion to adopt 20ppm, the 473 
FDA explicitly noted (Federal Register, 2013) that (i) concentrations as low as the NOAEL could not 474 
be verified analytically and (ii) such a low level risked depriving people with coeliac disease of 475 
products which would be safe for most of them. Moreover, they considered that a lack of such 476 
products could increase the risk to people with coeliac disease by limiting their choice of suitable 477 
products. The 20ppm threshold thus aims to protect the majority of persons with coeliac disease. It 478 
is based both on clinical data and on the ability to measure gluten at the suggested level. In the 479 
case of the US FDA, it also recognises that t e most effective level of protection may not be that 480 











Together, these examples show that current problems are handled: 483 
- In a pragmatic rather than risk-based manner: e.g. acrylamide, focusing on lowering levels 484 
without necessarily aiming for safe levels  485 
- In a pragmatic, risk-based way: e.g. Campylobacter, focusing on lowering levels and taking 486 
into account additional factors such as the economic i pact 487 
- By setting acceptable intake levels for the general population only, excluding the most 488 
sensitive individuals e.g. for histamine  489 
- By setting a threshold aiming to protect the majority of a sensitive population, e.g. threshold 490 
for gluten (majority of people with coeliac disease ar  protected), remaining mindful of the 491 
possibility that a more stringent criterion could paradoxically increase risk 492 
- By setting a threshold based on the detection limit, e.g. for sulphites, but a risk-based 493 
approach indicates this level likely protects the population. 494 
6 A framework to move forwards 495 
A framework for defining tolerable risk: outline  496 
Hunter and Fewtrell (2001) discussed acceptable and tolerable risk in the context of drinking water 497 
quality standards, sketching the outline of a framework in which acceptable and tolerable risk could 498 
be derived (Hunter and Fewtrell, 2001). More recently, Murphy and Gardoni (2008) proposed several 499 
criteria for approaches to defining tolerable and acceptable risks. These include that 500 
- All relevant factors are taken into account in an appropriate way. 501 
- Required data inputs are accurate, available and accessible 502 
- An approach should provide concrete practicable and theoretically justified information and 503 
conclusions on what types of action to take (or not)504 
- Value judgements and method of approach should be transparent 505 











Figure 3 attempts to depict the relationship between the Murphy and Gardoni (2008) criteria listed 508 
above and how a proposed framework for defining tolerable risk could operate in terms of what needs 509 
to be taken into account, how and by whom as discussed in detail in this section. 510 
 511 
Figure 3. Outline of a framework to help define an appropriate level of protection for consumers with food 512 
allergies. This framework is based on the criteria developed by Murphy and Gardoni (2008). Our proposed 513 
framework aims, in a transparent way, to take into account all relevant factors and diversity of views needed to 514 
reach a consensus for establishing a tolerable risk and subsequently management thresholds for an appropriate 515 
level of protection in food-allergic consumers arising through the unintended presence of allergen(s) i  food 516 
products. This should lead to an improved and fair decision-making that is better accepted by society.  517 
 518 
 519 
- All relevant factors taken into account: Two key factors underlie the tolerability of the risk 520 
posed by food allergens: the proportion of the food-allergic population who are affected, and 521 
the health consequences for these individuals. Referenc  doses encapsulate the first part, as 522 










also provide some information about the second elemnt – the likely severity of the reaction – 524 
although the ability to predict severity is hampered by the multiplicity of influencing factors 525 
(Dubois et al., 2018). New knowledge on the impact of exercise and sleep deprivation have 526 
also recently emerged to improve our understanding of some of these variables (Dua et al., 527 
2019). However, assessment of the value of Referenc Doses should not only be based on a 528 
simplistic interpretation of the proportion predicted to react, but attempt to form a judgement 529 
about the likelihood that any reactions would be “harmful to human health”, to borrow a term 530 
used in the USA’s allergen labelling legislation. The possible harm done by not implementing 531 
Reference Doses should also receive consideration, including, for instance, the uncertainty 532 
and anxiety experienced by people with food allergies as a result of an inconsistent and 533 
excessive use of PAL 534 
- In managing the risk from allergens, Reference Doses (derived from human provocation 535 
studies) can be used, but these need to be translated into action levels (defined in Table 1), 536 
which reflect tolerable concentrations after taking to consideration the amount of food 537 
consumed by an individual. In this case additional relevant factors come into play, such as 538 
assumptions about portion size eaten. Although not directly relevant for defining an 539 
appropriate level of protection, the ability of analytical methods also enters into play in the 540 
practical application of action levels. 541 
- Beyond the biology, selection of appropriate Reference Doses may also need to consider 542 
behavioural factors, such as understanding and adherenc  to PAL, as well as unintended 543 
consequences, such as impact on consumer choice and also cost to the consumer (products 544 
which are labelled as suitable following a risk-assessment could cost more, impinging on 545 
consumer choice) (Remington et al., 2015). 546 
- Required data inputs are accurate, available and accessible: common standards are 547 
developed for inclusion and exclusion of data used for dose-distribution modelling, and 548 
appropriate steps are taken to enable these data to be shared or be accessible for review while 549 
protecting the rights and obligations of the owners of the data including privacy protection 550 










publication of Westerhout et al. (2019). This could form the basis of quality standards for data 552 
in a common curated database, allowing sharing of data as mathematical formulas or full 553 
population ED-distribution details, making true availability and accessibility possible. 554 
- An approach should provide concrete practicable and theoretically justified information 555 
and conclusions on what types of action to take (or not): 556 
o Implementation of Reference Doses or action levels would meet this criterion, 557 
supported by further studies such as single dose challenge studies (Hourihane et al., 558 
2017) to validate predicted values and the health consequences of exposure. 559 
o PAL is currently, and is likely to remain, an important approach for managing and 560 
mitigating the risk from unintended allergen presence. Reference doses guide risk 561 
managers on the level of risk beyond which PAL is required; if no other mitigation is 562 
possible. Reference doses are, however, the starting poi t, and clear guidance on the 563 
application of PAL, including its verification, is needed to support their introduction. 564 
At a minimum, this should include guidance on allergen risk assessment, as well as 565 
the application of analytical methods and meaningful sampling. 566 
- Value judgements and method of approach should be transparent: A value judgement is a 567 
judgment of the rightness or wrongness of something or someone, or of the usefulness of 568 
something or someone. A value judgment can refer to a judgment based upon a particular set 569 
of values or on a particular value system. We do not make value-free judgements, therefore in 570 
risk assessment we need to think about how we make v lu  judgements responsibly and how 571 
we communicate those value judgements. In order to do this, we need to be aware of our own 572 
biases when developing and communicating a framework. Identification of value judgements 573 
can be aided by conducting peer review, interdisciplinary working and engaging consumer 574 
involvement. Applying this to Reference Doses, their theoretical basis and potential utility 575 
should be clear to all stakeholders within the food allergy community. The latter should be 576 
invited to share their views on them, also understanding that they can influence the outcomes. 577 
- The approach should describe the societal distribution of the risks: only people with food 578 










which they are reactive, but the consequences of living with someone with a food allergy 580 
extend to their family and beyond. The fact that food allergy risks can be mitigated – but not 581 
necessarily eliminated – needs to be acknowledged; appropriate efforts must be made to 582 
quantify the risks as accurately as possible in order for allergic consumers and their families 583 
to take informed decisions about possible exposure below the Reference Dose.  Of note, 584 
allergic consumers are already at risk from the current situation, something which would be 585 
reduced if Reference Doses were implemented as discussed above. Beyond that, other 586 
stakeholders currently face risks which need to be considered, for example for food 587 
businesses which may be required to undertake product recalls because of an enforcement 588 
decision which is not currently supported by the scientific evidence. This also could be 589 
reduced if Reference Doses were implemented. 590 
 591 
The purpose of the framework is to ensure, in a systematic manner, that any criteria deemed to be 592 
necessary for the equitable definition of tolerable risk are formally applied. This should ensure that 593 
the Reference Doses and/or action levels defined enjoy wide support. In practice, this would mean 594 
that all relevant stakeholders are involved, that all relevant points are taken into account, and thatany 595 
decisions are taken systematically and in a transparent manner. This approach will help to ensure in 596 
particular that the conclusions reached earn the trust of those affected, as well as wider society. 597 
 598 
Who should or needs to be involved? 599 
 600 
Defining tolerable risk is a societal activity. Most, if not all discussions of tolerable risk, irrespctive 601 
of the field under consideration, recognize that failure to involve all relevant stakeholders in defining 602 
tolerable risk will most likely result in sub-optimal decisions (Hunter and Fewtrell, 2001; Murphy and603 
Gardoni, 2008). Unsurprisingly, such outcomes carry  strong likelihood that they are distrusted by 604 
those who have to bear that risk, who are often the least likely to be included in discussions, creating a 605 
barrier to adoption. This aspect is also reflected in the Murphy and Gardoni (2008) criteria mentioned 606 










subpopulations. At a minimum, a framework pertaining to food allergy demands the involvement of 608 
risk assessors and managers, regulators, jurists, representatives of those with food allergies (including 609 
any vulnerable subpopulations) and food business operators. 610 
 611 
Risk assessors will characterize the risk in terms of how it relates to variables which can be 612 
controlled, such as amount of allergen and frequency of reaction, any factors which may aggravate or 613 
mitigate the risks, and associated uncertainties. 614 
 615 
Risk managers will use the risk assessment as a basis for their decisions, effectively representing the616 
societal input. A good understanding of what risk i tolerable, the output which the framework is 617 
meant to develop, should result in better-founded dcisions, more accurately reflecting societal views 618 
on the risk and its tolerability, with appropriate w ight given to the views of different stakeholders. 619 
 620 
Jurists and regulators help to develop and implement the legal framework that delivers the intentions 621 
of society as elucidated through the framework. 622 
 623 
Representatives of those with food allergies are a critical stakeholder to both educate other 624 
stakeholders about what it means to live with the risk, and how that could be improved. They will 625 
understand what works in practice for the allergic consumer, and what does not, and be able to convey 626 
the views of other stakeholders to their constituency. Patient Representative Organisations will thus 627 
contribute a synthesis of an overall patient view, if necessary soliciting input beyond their members 628 
alone, informed by their interactions with allergic consumers and their carers. In discharging their 629 
role, they may also need to call on other expertise, such as that of clinicians, scientific experts, ec.630 
 631 
Representatives of food business operators will contribute knowledge about practicalities of managing 632 
operations. Similar to patient organisations, they will need to ensure contributions from the diversity 633 










What does the framework need to include? 636 
 637 
The risk posed by food allergens ranges from mild, transient signs and symptoms to systemic 638 
reactions and anaphylaxis, which are in general tretable but can occasionally be fatal (Turner et al., 639 
2019). What may be judged tolerable will sit within two dimensions, namely (i) numbers at risk of 640 
reacting, as measured  through epidemiological and clinical studies and (ii) the characteristics 641 
(severity) of any resulting reaction. Other ILSI exp rt groups have also identified these two factors as 642 
critical and proposed ways in which they could be addressed, albeit in a different context (Houben et 643 
al., 2016). The impact of food allergy extends beyond the experience of an allergic reaction, and the 644 
adverse effect on health-related quality of life due to high levels of anxiety is well-documented in 645 
both food-allergic individuals and their carers (Howe et al., 2014; Walkner et al., 2015). All these 646 
aspects could be evaluated in the context of a capabilities-based derivation of tolerable risk proposed 647 
by Murphy and Gardoni (2008), specifically the extent to which a risk degrades the ability of 648 
individuals to lead the kind of life they have reason to value. For food-allergic consumers and those 649 
purchasing food for them, this includes an ability to make informed (food) choices which are safe for 650 
them, allowing them to enjoy a good quality of life and minimise the worry and anxiety associated 651 
with the risk of accidental allergic reactions. 652 
 653 
The framework therefore needs to define carefully what is required of the risk assessment in terms of 654 
data types and quality. Beyond this, it will also need to consider the criteria upon which tolerability s 655 
based, and how they would be met satisfactorily in the context of food allergy and the diverse nature 656 
of stakeholders affected by it. These will vary across different stakeholders, and users of the 657 
framework will need to reach a consensus on prioritising them, appropriately balancing the needs of 658 
those stakeholders. 659 
 660 











Those involved in the determination of tolerable risk within the proposed framework will start with a 663 
diversity of views, possibly even contradictory and antagonistic. The framework must facilitate the 664 
expression of these opinions, allowing meaningful contributions from all stakeholders. Approaches 665 
such as a Delphi process may be helpful in this regard, helping to assemble the evidence required and 666 
analyse it to identify implications. Our proposed framework does not aim to circumscribe those who 667 
will use it, but rather to describe the elements which need to be included. Those operating the 668 
framework will therefore need to decide at the outset on the desired outputs. This could range from 669 
scrutinising the basis of Reference Doses to gathering data on health-related quality of life. 670 
Ultimately, defining a tolerable risk, which is accepted beyond the group itself, will depend on the 671 
degree of consensus achieved. 672 
7 Conclusion 673 
Defining an appropriate level of protection from the risks to food-allergic consumers due to the 674 
unintended presence of allergen(s) in food products remains a pressing priority. Lack of regulation has675 
resulted in proliferation of different risk mitigation strategies, leaving food-allergic individuals 676 
uncertain and confused about the safety of food proucts. This impairs their ability to make safe food 677 
choices – one of the aims of the Food Information fr Consumers Regulation (European Parliament 678 
and Council, 2011), a pivotal piece of consumer safety legislation.  679 
 680 
In contrast the science behind setting safe Referenc  Doses and action levels, an essential foundation 681 
to defining tolerable risk in the context of food allergy, grows ever more robust. Advances in 682 
modelling utilising the ever more abundant data from human provocation studies, including single 683 
dose challenges, are helping to validate inferences about exposure to low doses of allergen and better 684 
understand the impact of co-factors. However, Reference Doses and approaches to allergen risk 685 
assessment are not yet harmonised in any jurisdiction, even in the European Union where a legislative 686 
framework exists. Abundance of data of sufficient quality is clearly insufficient by itself to allow 687 
decisions on tolerable risk, highlighting the urgent need to understand and integrate into the process 688 











We have reviewed the factors contributing to tolerable risk decisions and how they were made for a 691 
diverse range of other foodborne hazards. We found that neither the actual target level of protection, 692 
nor the process used to derive it, are commonly described sufficiently for the underlying rationale to 693 
be transparent to all stakeholders. Of note, we were unable to find evidence of the process leading to 694 
the decision on acceptable risks in the examples investigated nor have we always been able to identify 695 
all the stakeholders contributing to the risk decision. These observations illustrate the lack of 696 
transparency behind these processes. We noted that notwithstanding the presence of residual risks, 697 
risk management measures were always instituted to mitigate those food safety risks. The examples 698 
demonstrate that decisions on risk level can be takn despite residual uncertainty, illustrating the ne d 699 
to progress from the risk assessment stage to risk management measures, even if risk is minimised 700 
rather than eliminated. Furthermore a diversity of rationales led to the conclusions, ranging from 701 
analytical capability to health-based criteria, butalso in one case integrating wider socio-economic 702 
considerations affecting the ultimate risk (the FDA’s assessment for coeliac disease). 703 
 704 
Lack of agreement on a tolerable level of residual risk in food allergy has hindered the development 705 
of effective risk management approaches and has rende d one measure – precautionary allergen 706 
labelling – almost meaningless, to the serious detrim nt of people with food allergies and other 707 
stakeholders. To address this issue we proposed a framework for the definition of tolerable risk based 708 
on the criteria developed by Murphy and Gardoni (2008). Reviewing these criteria with respect to 709 
food allergy, we concluded that sufficient knowledg exists to implement the framework, including 710 
sufficient expertise across the whole range of stakeholders with an interest in the outcome to allow 711 
opinions to be heard and respected, and a consensus to be achieved. A strength of our proposal is that712 
it advocates a fully transparent process which should lead to better and more equitable decisions 713 
which are better accepted by society. The framework is also equally applicable to allergens that are 714 











As highlighted by Hunter and Fewtrell (2001), as well as Murphy and Gardoni (2008), failure to 717 
involve all relevant stakeholders in defining tolerable risk will most likely result in sub-optimal risk 718 
management decisions, or decisions that are not supported by those bearing the risk. We therefore 719 
hope that this publication will trigger the much-need d cross-stakeholder engagement and 720 
collaboration to finally define appropriate levels of protection for food-allergic consumers. We hope 721 
Competent Authorities will understand the urgent need, and see that – of all the stakeholders – their 722 
role provides an ideal opportunity to champion and lead this activity. 723 
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Can we define a level of protection for allergic consumers that 
everyone can accept? 
Highlights: 
• Quantitative limits for unintended allergen presence have in general not been defined across and 
within jurisdictions. 
• Inability to define what risk is tolerable is a major obstacle to defining those limits.  
• Diverse approaches (pragmatic to risk-based) have been adopted to define quantitative limits for 
other food safety hazards. 
• How tolerability decisions were reached in the case of those hazards is unclear. 
• We propose a framework for transparent decisions on risk tolerability, founded on full 
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